New FDA Warning Added to Popular Weight Loss Drugs
Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration during general anesthesia or deep sedation. The affected drugs are liraglutide (Saxenda, Victoza), semaglutide (Ozempic, Rybelsus, Wegovy), and tirzepatide (Mounjaro, Zepbound).
A stronger Ozempic, Wegovy sales boom, and Hims' generic weight loss drug: Pharma news roundup
Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, continued to soar in the third quarter,
Hosted on MSN1mon
Ozempic's cousin drug liraglutide is about to get cheaper. But how does it stack up?The drug, liraglutide, is sold under the brand names Victoza and Saxenda. Patents for Victoza and Saxenda have now expired. So other drug companies are working to develop "generic" versions.
Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...
17don MSN
The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...
Lexaria Bioscience (LEXX) received partial 12-week blood sugar results from the recently completed animal study WEIGHT-A24-1. The company said, ...
CVS Caremark and Express Scripts, along with GoodRx and others, are accused of working together to suppress reimbursements to independent pharmacies in at least three class-action lawsuits. Also, Hims ...
Ozempic (semaglutide) and Victoza (liraglutide) are prescription drugs used to treat type 2 diabetes and reduce the risk of cardiovascular problems. Both drugs come as an injection. Ozempic and ...
Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. How much weight a person loses on liraglutide or ...
Diabetes Care. 2015;38(6):1058-1066. The safety profile of liraglutide is under continuous surveillance through meticulous routine pharmacovigilance, with any cases of pancreatitis being analyzed ...
Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback